MedTrace Logo

Vaginal Progesterone Against a Second Attack of Antepartum Haemorrhage in Placenta Previa Women

NCT04725929 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2022-06-09

No results posted yet for this study

Summary

Placenta praevia is associated with an increased risk of preterm delivery (PTD) especially if associated with bleeding and uterine contractions .

In this study we will determine the effect of Progesterone in preventing a second attack of antepartum haemorrhage in pregnant women diagnosed with placenta previa

Conditions

  • Placenta Previa

Sponsors & Collaborators

  • Nourhan Ashraf ElSherbiny

    lead OTHER

Principal Investigators

  • Mahmoud Ghaleb, MD · Ain Shams Maternity Hospital

Eligibility

Min Age
24 Weeks
Max Age
34 Weeks
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2021-06-01
Completion
2021-07-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04725929 on ClinicalTrials.gov